Pembrolizumab (Keytruda)
Treatment for Bladder Cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
65%
Safety Score
50%
Clinical Trials
117
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
3-6 months
Treatment Duration
Up to 2 years or until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$7,500
Side Effect Mgmt:$10,000
Total Annual:$147,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$590,000
Cost per Remission
$2,107,142.86
Comparison vs Taxane chemotherapy (e.g., Paclitaxel)
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (Keytruda) Outcomes
for Bladder Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+25%
Remission Rate
+7%
Common Side Effects
Fatigue
+25%
Pruritus (itching), rash
+20%
Diarrhea/Colitis
+12%
Hypothyroidism
+7%
Pneumonitis, hepatitis, nephritis (severe irAEs)
+3%
Active Clinical Trials
6 active trials recruiting for Pembrolizumab (Keytruda) in Bladder Cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163ACTIVE NOT RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jun 27, 2018
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600RECRUITINGPHASE2
54 participants
INTERVENTIONAL
Beijing, China
Started: Dec 7, 2021
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
NCT05879653RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Kobe, Japan +3 more
Started: Oct 1, 2023
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185ACTIVE NOT RECRUITINGPHASE3
520 participants
INTERVENTIONAL
Washington D.C., United States +133 more
Started: May 19, 2020
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
NCT02560636ACTIVE NOT RECRUITINGPHASE1
34 participants
INTERVENTIONAL
Sutton, United Kingdom
Started: Jun 6, 2016
Pembrolizumab in Muscle-invasive Bladder Cancer
NCT05406713ACTIVE NOT RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Duarte, United States +3 more
Started: Jul 13, 2022
Completed Clinical Trials
7 completed trials for Pembrolizumab (Keytruda) in Bladder Cancer
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
NCT02736266COMPLETEDPHASE2
174 participants
INTERVENTIONAL
Milan, Italy
Started: Feb 27, 2017
MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324582COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Springfield, United States +2 more
Started: Jun 1, 2015
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NCT02621151COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Chicago, United States +4 more
Started: Aug 11, 2016
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
NCT03212651COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Villejuif, France
Started: Oct 17, 2017
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
NCT02178722COMPLETEDPHASE1, PHASE2
444 participants
INTERVENTIONAL
La Jolla, United States +23 more
Started: Jul 17, 2014
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
NCT03319745COMPLETEDPHASE2
23 participants
INTERVENTIONAL
Houston, United States
Started: Jan 11, 2018
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
NCT02619253COMPLETEDPHASE1
52 participants
INTERVENTIONAL
Los Angeles, United States +3 more
Started: Feb 23, 2016
Showing 20 of 139 total trials